Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Schrödinger, Inc.
SDGR
NASDAQ·Healthcare·Software - Application·Mkt cap $1.2B
$16.88
▲ +2.99%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$10.95 - $23.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 21.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary physics-based computational platform with 30+ years of R&D investment
- Dual revenue model combining high-margin software licensing with drug discovery validation
- Integrated platform spanning target identification, lead optimization, and preclinical development
- Established customer base including major pharmaceutical companies and research institutions
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Moderate growth ahead
Increasing adoption of AI and computational chemistry in drug discovery workflows
Value
Deep value opportunity - significant discount to Healthcare IT & Services peers
Momentum
Hot
+41.5% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SDGR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 5, 2026
Reported EPS of -$0.81 vs -$0.56 consensus (-44.6% surprise). Revenue of $58.6M vs $47.6M expected (+23.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-44.6%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+19%
+63%
+16%
+54%
-1%
-2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$47.3M
$35.3M
$88.3M
$59.6M
$54.8M
$54.3M
$87.2M
$58.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
-102.5%
Wall Street consensus
3 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · May 14, 2026